BaseLaunch announces a new partnership with AbbVie
Further strengthens BaseLaunch's global pharma industry partnerships
Further strengthens BaseLaunch's global pharma industry partnerships
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Launch of 20 new medicines expected by 2030
The collaboration aims to bolster healthcare entrepreneurship
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
EBITDA before special items falls 1.3 percent to € 4.41 billion
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
The project funding will be done through a mix of internal accruals and debts.
Subscribe To Our Newsletter & Stay Updated